Acurx rises on filing patent application for bacterial infection therapy

Acurx Pharmaceuticals

07/07/2021 14:52

** Shares of biopharma co  ACXP.O  rise ~2.4% to $5.68
    ** Co files provisional patent application in U.S. Patent
and Trademark Office for its experimental drug, ibezapolstat,
and its use to treat C. difficile Infection  urn:newsml:reuters.com:*:nPn8Zwp0Ka
    ** C. diff is a type of bacteria that can cause colitis, a
serious inflammation of colon; it is one of the most common
causes of health care-associated infections in U.S. hospitals
    ** Stock debuted on Nasdaq on June 25 and has fallen 28% 
from its IPO price

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))